329 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (329)
- Addiction (4)
- Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (2)
- Blood Disorders (2)
- Bone & Muscle (2)
- Cancer (88)
- COVID-19 (Coronavirus) (8)
- Diabetes (6)
- Ear, Nose and Throat (6)
- Endocrine & Metabolic Disease (1)
- Gastrointestinal and Digestive Diseases (5)
- Hair and Skin Disorders (2)
- Healthy Volunteers (45)
- Heart Disease (21)
- Infectious Disease (12)
- Liver Disease (13)
- Lung Disease (2)
- Neurological Disorders (42)
- Nutrition (1)
- Obesity (7)
- Obstetrics & Gynecology (12)
- Pediatrics (21)
- Psychiatric Disorders (7)
- Rehabilitation (1)
- Stroke (1)
- Transplant (16)
- Vascular Conditions (1)
Displaying 1 - 12 of 12
Condition: Cancer / Pancreatic Cancer
Investigator: Fay Kastrinos, MD
Status: Currently Recruiting
Pancreatic cancer is a deadly disease and the best hope for improving the chances of survival is to find it early. Some patients, called "high risk", have an inherited predisposition to pancreatic cancer. Certain medical centers have started programs where "high risk patients" undergo testing, such as receiving imaging scans, to look for…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The purpose of this study is to collect and store donated blood samples and associated medical data from participating subjects to help develop an ovarian cancer blood test and for potential research into other gynecological diseases.
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The purpose of this research study is to learn if sacituzumab govitecan (also called SG) can improve lifespan and delay the growth or spread of the disease in participants with endometrial cancer when compared to chemotherapy (doxorubicin or paclitaxel). Sacituzumab govitecan is a type of drug called an antibody-drug conjugate. An antibody-drug conjugate (…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The purpose of the study is to compare how well Rina-S works against ovarian cancer, primary peritoneal cancer, or fallopian tube cancer compared to chemotherapy drugs that are already approved and used for your type of cancer. You have an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. Rina-S is not…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The purpose of this clinical research study is to develop a sample collection method that is less invasive than current endometrial sampling methods (uterine sample collection) and develop a diagnostic test from these samples which is as informative in diagnosing the absence of endometrial (uterine) cancer as currently available methods.
Condition: Cancer / Pancreatic Cancer
Investigator: Susan Bates, MD
Status: Currently Recruiting
The purpose of this study is to determine whether the drug, bethanechol, could potentially be used in combination with chemotherapy regimen gemcitabine and nab-paclitaxel and surgery to decrease the chance of the cancer coming back after it is removed. Animal models have shown that treatment with bethanechol can inhibit cancer growth and spread. The…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The goal of this clinical research study is to compare the outcomes of minimally invasive surgery (the investigational surgery) to laparotomy (the current standard of care) in women with Epithelial Ovarian Cancer (EOC) who receive chemotherapy before and after surgery. Researchers want to learn if one surgery can prevent the disease from returning for…
Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Currently Recruiting
The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus atezolizumab and mFOLFIRINOX compared with mFOLFIRINOX (standard of care chemotherapy) alone on patients with resected pancreatic ductal adenocarcinoma (PDAC). In this study, the participant will get either the combination of autogene cevumeran plus atezolizumab and…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Currently Recruiting
The main purpose of this study is to learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove…
Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Currently Recruiting
The main goal of this study is to find out if treatment with zimberelimab and stereotactic body radiation therapy alone or in combination with quemliclustat, with or without etrumadenant, given before surgery is safe and if it can further increase the immune response against the tumor.
Condition: Cancer / Pancreatic Cancer
Investigator: Ryan Moy, MD
Status: Currently Recruiting
The goal of this study is to see if a study drug called ASP2138 is safe and effective for people diagnosed with tumors known to have Claudin (CLDN) 18.2 expression. CLDN is a group of proteins seen in gastric-specific, gastroesophageal junction (GEJ) or pancreatic cancer types. The study will also see how ASP2138 is processed in the blood. Each participant…
Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Currently Recruiting
The purpose of this study is to determine if a combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing tumor size and prolonging life in patients with advanced pancreas cancer. The treatment consists of both immunotherapy (cemiplimab and motixafortide) and chemotherapy (gemcitabine and nab-paclitaxel…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE